TY - JOUR
T1 - Heart rate, arterial pressure and propofol-sparing effects of guaifenesin in dogs
AU - Hristova, Teodora S.
AU - Keating, Stephanie CJ
AU - McCoy, Annette M.
AU - Strahl-Heldreth, Danielle E.
AU - Doodnaught, Graeme M.
AU - Sieja, Kelly M.
AU - Swanson, Kelly S.
N1 - Publisher Copyright:
© 2022 Association of Veterinary Anaesthetists and American College of Veterinary Anesthesia and Analgesia
PY - 2023/1
Y1 - 2023/1
N2 - Objective: To evaluate the heart rate (HR) and systemic arterial pressure (sAP) effects, and propofol induction dose requirements in healthy dogs administered propofol with or without guaifenesin for the induction of anesthesia. Study design: Prospective blinded crossover experimental study. Animals: A total of 10 healthy adult female Beagle dogs. Methods: Dogs were premedicated with intravenous (IV) butorphanol (0.4 mg kg–1) and administered guaifenesin 5% at 50 mg kg–1 (treatment G50), 100 mg kg–1 (treatment G100) or saline (treatment saline) IV prior to anesthetic induction with propofol. HR, invasive sAP and respiratory rate (fR) were recorded after butorphanol administration, after guaifenesin administration and after propofol and endotracheal intubation. Propofol doses for intubation were recorded. Repeated measures analysis of variance (ANOVA) was used to determine differences in propofol dose requirements among treatments, and differences in cardiopulmonary values over time and among treatments with p < 0.05 considered statistically significant. Results: Propofol doses (mean ± standard deviation) for treatments saline, G50 and G100 were 3.3 ± 1.0, 2.7 ± 0.7 and 2.1 ± 0.8 mg kg–1, respectively. Propofol administered was significantly lower in treatment G100 than in treatment saline (p = 0.04). In treatments G50 and G100, HR increased following induction of anesthesia and intubation compared with baseline measurements. HR was higher in treatment G100 than in treatments G50 and saline following induction of anesthesia. In all treatments, sAP decreased following intubation compared with baseline values. There were no significant differences in sAP among treatments. fR was lower following intubation than baseline and post co-induction values and did not differ significantly among treatments. Conclusions and clinical relevance: When administered as a co-induction agent in dogs, guaifenesin reduced propofol requirements for tracheal intubation. HR increased and sAP and fR decreased, but mean values remained clinically acceptable.
AB - Objective: To evaluate the heart rate (HR) and systemic arterial pressure (sAP) effects, and propofol induction dose requirements in healthy dogs administered propofol with or without guaifenesin for the induction of anesthesia. Study design: Prospective blinded crossover experimental study. Animals: A total of 10 healthy adult female Beagle dogs. Methods: Dogs were premedicated with intravenous (IV) butorphanol (0.4 mg kg–1) and administered guaifenesin 5% at 50 mg kg–1 (treatment G50), 100 mg kg–1 (treatment G100) or saline (treatment saline) IV prior to anesthetic induction with propofol. HR, invasive sAP and respiratory rate (fR) were recorded after butorphanol administration, after guaifenesin administration and after propofol and endotracheal intubation. Propofol doses for intubation were recorded. Repeated measures analysis of variance (ANOVA) was used to determine differences in propofol dose requirements among treatments, and differences in cardiopulmonary values over time and among treatments with p < 0.05 considered statistically significant. Results: Propofol doses (mean ± standard deviation) for treatments saline, G50 and G100 were 3.3 ± 1.0, 2.7 ± 0.7 and 2.1 ± 0.8 mg kg–1, respectively. Propofol administered was significantly lower in treatment G100 than in treatment saline (p = 0.04). In treatments G50 and G100, HR increased following induction of anesthesia and intubation compared with baseline measurements. HR was higher in treatment G100 than in treatments G50 and saline following induction of anesthesia. In all treatments, sAP decreased following intubation compared with baseline values. There were no significant differences in sAP among treatments. fR was lower following intubation than baseline and post co-induction values and did not differ significantly among treatments. Conclusions and clinical relevance: When administered as a co-induction agent in dogs, guaifenesin reduced propofol requirements for tracheal intubation. HR increased and sAP and fR decreased, but mean values remained clinically acceptable.
KW - co-induction
KW - dog
KW - guaifenesin
KW - propofol
UR - http://www.scopus.com/inward/record.url?scp=85143495936&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85143495936&partnerID=8YFLogxK
U2 - 10.1016/j.vaa.2022.10.001
DO - 10.1016/j.vaa.2022.10.001
M3 - Article
C2 - 36344374
AN - SCOPUS:85143495936
SN - 1467-2987
VL - 50
SP - 50
EP - 56
JO - Veterinary Anaesthesia and Analgesia
JF - Veterinary Anaesthesia and Analgesia
IS - 1
ER -